Details for New Drug Application (NDA): 022517
✉ Email this page to a colleague
NDA 022517 describes NOCDURNA, which is a drug marketed by Ferring Pharms Inc and is included in one NDA. There are four patents protecting this drug. Additional details are available on the NOCDURNA profile page.
The generic ingredient in NOCDURNA is desmopressin acetate. There are twenty drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the desmopressin acetate profile page.
The generic ingredient in NOCDURNA is desmopressin acetate. There are twenty drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the desmopressin acetate profile page.
Summary for 022517
| Tradename: | NOCDURNA |
| Applicant: | Ferring Pharms Inc |
| Ingredient: | desmopressin acetate |
| Patents: | 4 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;SUBLINGUAL | Strength | 0.0277MG | ||||
| Approval Date: | Jun 21, 2018 | TE: | RLD: | Yes | |||||
| Patent: | ⤷ Start Trial | Patent Expiration: | May 21, 2029 | Product Flag? | Substance Flag? | Delist Request? | |||
| Patented Use: | TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS, COMPRISING MONITORING A PATIENT'S SERUM SODIUM CONCENTRATION | ||||||||
| Patent: | ⤷ Start Trial | Patent Expiration: | May 21, 2029 | Product Flag? | Substance Flag? | Delist Request? | |||
| Patented Use: | TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS, COMPRISING MONITORING A PATIENT'S SERUM SODIUM CONCENTRATION | ||||||||
| Patent: | ⤷ Start Trial | Patent Expiration: | Apr 13, 2030 | Product Flag? | Substance Flag? | Delist Request? | |||
| Patented Use: | TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS | ||||||||
Expired US Patents for NDA 022517
Complete Access Available with Subscription
